Neurenati Therapeutics is a biotechnology company that develops therapeutics for gastrointestinal rare diseases.
Neurenati Therapeutics has raised $1.7M in total funding. The most recent round was Seed. The last funding was announced in April 2024.
Neurenati Therapeutics's investors include Investissement Quebec, Genson Capital.
Neurenati Therapeutics is headquartered in Montreal, Canada.
Neurenati Therapeutics is a biotechnology company that develops therapeutics for gastrointestinal rare diseases.
Neurenati Therapeutics is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Neurenati Therapeutics — Funding & Investors." VCBacked, April 18, 2024, https://www.vcbacked.co/company/neurenati-therapeutics. Accessed October 29, 2026.
VCBacked. (2024). Neurenati Therapeutics — Funding & Investors. Retrieved October 29, 2026, from https://www.vcbacked.co/company/neurenati-therapeutics
{{cite web |title=Neurenati Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/neurenati-therapeutics |website=VCBacked |access-date=October 29, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated